GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (FRA:GPH) » Definitions » Valuation Rank

Galmed Pharmaceuticals (FRA:GPH) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Galmed Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Galmed Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (FRA:GPH) » Definitions » Valuation Rank
Comparable Companies
SCNI SXTP THAR MTNB ELAB QLGN GRTX ENVB REVB PBM VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
GLMD:USA
Address
16 Tiomkin Street, Tel Aviv, ISR, 6578317
Website
https://www.galmedpharma.com
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.